Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Novavax Inc (NQ: NVAX )

4.735 +0.065 (+1.39%)
Streaming Delayed Price Updated: 11:57 AM EDT, May 2, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Novavax Inc

< Previous 1 2 3 4 Next >
Shah Capital nominates two highly qualified independent director candidates for Novavax
From Shah Capital
Via GlobeNewswire
The Top 5 Analysts Ranked by Marketbeat and Stocks They Cover
Analysts rate the stocks, but who rates the analysts? This is a look at five of the highest-rated analysts tracked by Marketbeat.com based on 12-month ROI. 
Via MarketBeat
Topics Cannabis
Exposures Cannabis
Exploring Stocks with High Short Interest: INBS, BLNK, BYND, NVAX, PLUG
Via AB Newswire
Topics Electric Vehicles
Exposures COVID-19 Electric Vehicles
Novavax’s dispute resolution and upcoming earnings call
Novavax navigates legal settlements, earnings expectations, and competition, hoping their protein-based vaccines become a global health game-changer. 
Via MarketBeat
Topics Earnings
Exposures COVID-19 Financial
Novavax Inc. (NASDAQ: NVAX) Near the Top of Equities by Percentage Gain on 7/10
Via Investor Brand Network
Exposures COVID-19
Novavax Inc. (NASDAQ: NVAX) Leading the Way in Tuesday Trading Based on Percentage Gain
Via Investor Brand Network
Exposures COVID-19
2 Stocks That Doubled EPS Estimates and Flashing Buy Signals
The second quarter of the 2023 earnings season has drawn to a close. There were many surprises in every sector. However, there were some standout surprises with 
Via MarketBeat
Exposures COVID-19
Is Novavax Finally Turning Things Around?
Vaccine developer Novavax Inc. (NASDAQ: NVAX) stock shot up 28% following its Q1 2023 earnings report. The company specializes in vaccines for infectious disea 
Via MarketBeat
Exposures COVID-19
A Company With Solutions Against Emerging COVID Variants And Other Viral Infections To Combat Future Pandemic Threats
By Ernest Dela Aglanu, Benzinga 
Via TheNewswire.com
Topics Death Economy
Exposures COVID-19 Death Economy
Coronavirus Vaccine Market To Surpass $95 Billion By 2028
EQNX::TICKER_START (NASDAQ:SBFM),(NASDAQ:MRNA),(NASDAQ:NVAX),(NASDAQ:VIR),(NASDAQ:INO) EQNX::TICKER_END 
Via FinancialNewsMedia
Exposures COVID-19
MarketBeat Week in Review – 1/30 - 2/3
The markets are trending lower to end the week. It’s hard to figure out the markets after the blockbuster job report, but the MarketBeat team gave it a shot 
Via MarketBeat
Topics Artificial Intelligence Earnings Economy
Exposures Artificial Intelligence Financial Interest Rates
Novavax Shares Jumped in January While Others Slipped
Updated FDA Covid vaccine policy could've boosted NVAX shares at the end of January, when other pharma stocks slipped, but it may not affect the bottom line. 
Via MarketBeat
Exposures COVID-19 Product Safety
River Private Wealth announces new round of investment in Novavax, Inc
Via AB Newswire
2 Biotechs Making Waves With A Single Product in their Pipeline
Catalyst Pharmaceuticals and Harmony Bioscience each have a single product in their respective pipelines, and both show incredible promise. 
Via MarketBeat
While COVID-19 Drags On, Biotechs Introduce New Treatments & Vaccines to Combat Subvariants
EQNX::TICKER_START (OTCQB:BIXT),(NASDAQ:NVAX),(NYSE:PFE),(NASDAQ:MRNA),(NASDAQ:INO),(NASDAQ:BNTX) EQNX::TICKER_END 
Via FinancialNewsMedia
Exposures COVID-19
Is Pfizer Stock Still Worth Buying After the Pandemic?
Pharmaceutical giant Pfizer (NYSE: PFE) is literally synonymous with COVID-19 vaccines, and as a result, Pfizer stock continues to beat expectations. 
Via MarketBeat
Exposures COVID-19
MarketBeat: Week in Review 9/19 – 9/23
The sell-off in the market confirms that the global economy is slowing. What should you do? Here are some insights our analysts delivered for you this week 
Via MarketBeat
Topics Economy
Exposures Economy Interest Rates
Novavax Remains a Risk-On Stock in a Risk-Off Market
NVAX is a risk-on stock at a time investors are turning to risk-off assets. This article looks to see if Novavax still presents an opportunity for investors 
Via MarketBeat
Topics Earnings
Exposures Financial
Is it Time to Cash Out Novavax Stock?
Vaccine developer Novavax (NASDAQ: NVAX) stock has collapsed (-61%) in 2022. The Company’s protein-based COVID-19 vaccine Nuvaxovid has launched in Europe and awaits CDC approval for launch the U.S. 
Via MarketBeat
Exposures COVID-19 Product Safety
NOVAVAX INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Novavax, Inc. - NVAX
From Kahn Swick & Foti, LLC
Via Business Wire
NASDAQ:NVAX Long Term Investor Notice: Investigation of Potential Wrongdoing at Novavax, Inc.
San Diego, CA -- (SBWIRE) -- 03/14/2022 -- Certain directors of Novavax, Inc. are under investigation over potential breaches of fiduciary duties. 
Via SBWire
Final Deadline Today: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Novavax, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit
Exposures Financial Legal
NVAX Final Deadline: Bronstein, Gewirtz & Grossman, LLC Reminds Novavax, Inc. Shareholders of Class Action and Lead Deadline: January 11, 2022
From Bronstein, Gewirtz & Grossman, LLC
Via Business Wire
Deadline Tomorrow Alert: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Novavax, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit
Exposures Financial Legal
NOVAVAX DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors That a Class Action Lawsuit Has Been Filed Against Novavax, Inc. and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire, P.C.
Via Business Wire
NVAX DEADLINE: Kessler Topaz Meltzer & Check, LLP Reminds Investors of Novavax, Inc. of Deadline in Securities Fraud Class Action Lawsuit
From Kessler Topaz Meltzer & Check, LLP
Via Business Wire
NOVAVAX 96 HOUR DEADLINE ALERT: Former Louisiana Attorney General and Kahn Swick & Foti, LLC Remind Investors With Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Novavax, Inc. - NVAX
From Kahn Swick & Foti, LLC
Via Business Wire
Deadline Tuesday Notice: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Novavax, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit
Exposures Financial Legal
The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Novavax, Inc. (NVAX)
From The Law Offices of Frank R. Cruz
Via Business Wire
Deadline Tuesday Alert: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Novavax, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit
Exposures Financial Legal
< Previous 1 2 3 4 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.